Business Context and Reporting Period
Outlook Therapeutics, Inc. (OTLK), a Delaware corporation, filed this Form 8-K on February 18, 2026. The filing addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the Company's compliance with continued listing standards.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial metric disclosed is the trading price of the Company's common stock, which closed below $1.00 per share for the last 30 consecutive business days prior to the report date.
Material Changes
The material event reported is the receipt of a deficiency notice from the Nasdaq Listing Qualifications Staff. The notice states that the Company failed to meet the minimum closing bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). This deficiency has no immediate effect on the listing status but triggers a compliance timeline.
Guidance, Outlook, and Risks
- Compliance Timeline: The Company has 180 calendar days, until August 17, 2026, to regain compliance. To do so, the stock must close at or above $1.00 per share for 10 consecutive business days before the deadline.
- Remediation Options: If compliance is not achieved by the deadline, the Company may be eligible for an additional 180-day period if it meets other listing standards (excluding bid price) and notifies Nasdaq of its intent to cure, potentially via a reverse stock split.
- Delisting Risk: If the Company fails to cure the deficiency or is deemed ineligible for an extension, Nasdaq may issue a delisting notification. The Company retains the right to appeal such a determination, though success is not assured.
- Management Action: Management intends to actively monitor the stock price and evaluate options to resolve the deficiency.
Investor Verification Checklist
- Verify the current closing bid price of OTLK stock to assess the severity of the deficiency.
- Monitor the Company's stock price performance over the next 10 consecutive business days to determine if immediate compliance is possible.
- Review future filings for announcements regarding a potential reverse stock split or other capital structure changes.
- Check for any subsequent correspondence from Nasdaq regarding the Company's eligibility for an extension period.